Excellgene Overview

  • Founded
  • 2001
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 1

Excellgene General Information


Developer of a synthetic protein intended to provide protein expressions for complex projects. The company's products are cultivated in animal cells and simple antibodies through clone screening for identification of optimal match of physiology and genetics for highest yield, enabling the biopharma industry to scale-up transient gene expression in non-instrumented bioreactors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Primary Office
  • Route de l'Ile-aux-Bois 1A
  • 1870 Monthey
  • Switzerland
+41 024 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Excellgene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 11-Nov-2014 Completed Generating Revenue
To view Excellgene’s complete valuation and funding history, request access »

Excellgene Executive Team (5)

Name Title Board Seat Contact Info
Maria Wurm Chief Executive Officer
Sebastian Rheindorf-Zaorski Chief Strategy Officer
Florian Wurm Ph.D Co-Founder, Chairman & Chief Scientific Officer
George Hong Ph.D Chief Commercial Officer
Martin Schmid Chief Financial Officer
To view Excellgene’s complete executive team members history, request access »

Excellgene Board Members (1)

Name Representing Role Since
Florian Wurm Ph.D Excellgene Co-Founder, Chairman & Chief Scientific Officer 000 0000
To view Excellgene’s complete board members history, request access »

Excellgene Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Fondation The Ark Accelerator/Incubator 000 0000 000000 0
To view Excellgene’s complete investors history, request access »